This is a StreetInsider.com Premium Only Page

Seres Therapeutics (MCRB) –

May 8, 2024 10:01 AM Form 10-Q Seres Therapeutics, Inc. For: Mar 31

May 8, 2024 07:06 AM Form 8-K Seres Therapeutics, Inc. For: May 08

May 8, 2024 07:00 AM Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 7, 2024 05:18 PM Form 8-K Seres Therapeutics, Inc. For: May 01

May 7, 2024 06:00 AM Flagship Pioneering Unveils Prologue Medicines to Unlock the Therapeutic Potential of the Viral Proteome

May 6, 2024 04:01 PM Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2024 09:30 AM Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

Apr 23, 2024 07:01 AM Form 8-K Seres Therapeutics, Inc. For: Apr 19

Apr 9, 2024 07:00 AM Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Apr 8, 2024 04:45 PM Form 4 Seres Therapeutics, Inc. For: Apr 04 Filed by: Biondi Paul

Apr 8, 2024 04:45 PM Form 4 Seres Therapeutics, Inc. For: Apr 04 Filed by: Berenson Stephen

Apr 8, 2024 04:45 PM Form 4 Seres Therapeutics, Inc. For: Apr 04 Filed by: Ausiello Dennis A

Apr 8, 2024 04:45 PM Form 4 Seres Therapeutics, Inc. For: Apr 04 Filed by: Fraser Claire

Apr 8, 2024 04:45 PM Form 4 Seres Therapeutics, Inc. For: Apr 04 Filed by: Graves Kurt

Apr 8, 2024 04:45 PM Form 4 Seres Therapeutics, Inc. For: Apr 04 Filed by: Kender Richard N

Apr 8, 2024 04:45 PM Form 4 Seres Therapeutics, Inc. For: Apr 04 Filed by: Dere Willard H

Apr 8, 2024 04:31 PM Form 8-K Seres Therapeutics, Inc. For: Apr 04

Apr 8, 2024 08:00 AM Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences

Apr 5, 2024 12:23 PM Form SC 13G/A Seres Therapeutics, Inc. Filed by: BlackRock Inc.

Mar 28, 2024 07:00 AM Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 27, 2024 04:21 PM Form 4 Seres Therapeutics, Inc. For: Mar 25 Filed by: Thorell Marella

Mar 27, 2024 04:15 PM Form 3 Seres Therapeutics, Inc. For: Mar 25 Filed by: Thorell Marella

Mar 19, 2024 08:30 AM Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024

Mar 19, 2024 07:00 AM Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 6, 2024 03:03 PM Seres Therapeutics (MCRB) PT Lowered to $5 at Oppenheimer

Mar 6, 2024 07:55 AM Seres Therapeutics (MCRB) PT Lowered to $8 at Chardan Capital Markets

Mar 5, 2024 10:19 AM Form DEF 14A Seres Therapeutics, Inc. For: Mar 05

Mar 5, 2024 10:14 AM Form S-8 Seres Therapeutics, Inc.

Mar 5, 2024 10:02 AM Form 10-K Seres Therapeutics, Inc. For: Dec 31

Mar 5, 2024 07:06 AM Form 8-K Seres Therapeutics, Inc. For: Mar 05

Mar 5, 2024 07:00 AM Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Feb 28, 2024 07:00 AM Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

Feb 27, 2024 07:00 AM Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

Feb 26, 2024 07:06 AM Form 8-K Seres Therapeutics, Inc. For: Feb 24

Feb 26, 2024 07:03 AM Seres Therapeutics (MCRB) Appoints Marella Thorell as CFO

Feb 26, 2024 07:00 AM Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

Feb 23, 2024 04:07 PM Form PRE 14A Seres Therapeutics, Inc. For: Feb 22

Feb 16, 2024 09:49 PM Form 4 Seres Therapeutics, Inc. For: Feb 14 Filed by: DesRosier Thomas

Feb 16, 2024 09:42 PM Form 4 Seres Therapeutics, Inc. For: Feb 14 Filed by: Shaff Eric D.

Feb 16, 2024 09:31 PM Form 4 Seres Therapeutics, Inc. For: Feb 14 Filed by: Henn Matthew R.

Feb 16, 2024 09:29 PM Form 4 Seres Therapeutics, Inc. For: Feb 14 Filed by: Young Teresa L.

Feb 16, 2024 09:22 PM Form 4 Seres Therapeutics, Inc. For: Feb 14 Filed by: von Moltke Lisa

Feb 16, 2024 09:16 PM Form 4 Seres Therapeutics, Inc. For: Feb 14 Filed by: Ege David S.

Feb 16, 2024 09:14 PM Form 4 Seres Therapeutics, Inc. For: Feb 14 Filed by: Arkowitz David

Feb 12, 2024 12:24 PM Form SC 13G/A Seres Therapeutics, Inc. Filed by: JANUS HENDERSON GROUP PLC

Feb 9, 2024 09:50 AM Form SC 13G/A Seres Therapeutics, Inc. Filed by: FMR LLC

Jan 30, 2024 04:02 PM Form 8-K Seres Therapeutics, Inc. For: Jan 30

Jan 29, 2024 05:27 PM Form SC 13G Seres Therapeutics, Inc. Filed by: BlackRock Inc.

Jan 17, 2024 07:00 AM Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 16, 2024 07:25 AM Seres Therapeutics (MCRB) PT Lowered to $9 at Oppenheimer